ZA200802998B - Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases - Google Patents

Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases

Info

Publication number
ZA200802998B
ZA200802998B ZA200802998A ZA200802998A ZA200802998B ZA 200802998 B ZA200802998 B ZA 200802998B ZA 200802998 A ZA200802998 A ZA 200802998A ZA 200802998 A ZA200802998 A ZA 200802998A ZA 200802998 B ZA200802998 B ZA 200802998B
Authority
ZA
South Africa
Prior art keywords
protein kinases
inhibiting protein
pyrazolo
methods
pyrimidine derivatives
Prior art date
Application number
ZA200802998A
Other languages
English (en)
Inventor
Timothy J Guzi
Michael P Dwyer
Paruch Kamil
David A Parry
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200802998B publication Critical patent/ZA200802998B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200802998A 2005-10-06 2008-04-04 Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases ZA200802998B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72415805P 2005-10-06 2005-10-06

Publications (1)

Publication Number Publication Date
ZA200802998B true ZA200802998B (en) 2009-10-28

Family

ID=37943366

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802998A ZA200802998B (en) 2005-10-06 2008-04-04 Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases

Country Status (11)

Country Link
US (2) US20070082900A1 (fr)
EP (1) EP1942900B1 (fr)
JP (3) JP5152922B2 (fr)
CN (1) CN101360499B (fr)
BR (1) BRPI0616985B1 (fr)
CA (1) CA2627623C (fr)
NO (1) NO20082093L (fr)
NZ (1) NZ567151A (fr)
TW (1) TWI421078B (fr)
WO (1) WO2007044441A2 (fr)
ZA (1) ZA200802998B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
US20090069315A1 (en) * 2006-03-08 2009-03-12 Rajeev Sivasankaran Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
WO2007139732A1 (fr) * 2006-05-22 2007-12-06 Schering Corporation Pyrazolo [1, 5-a] pyrimidines en tant qu'inhibiteurs de cdk
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
CA2686848A1 (fr) 2007-05-08 2008-11-20 Schering Corporation Procedes de traitement par formulations intraveineuses comprenant du temozolomide
CA2689667A1 (fr) * 2007-06-07 2008-12-18 Schering Corporation Synthese d'aminopyrazoles substitues en position 3
JP2011503084A (ja) * 2007-11-07 2011-01-27 シェーリング コーポレイション 新規の細胞周期チェックポイント調節剤およびこれらの調節剤とチェックポイント阻害剤との併用
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
CA2711614A1 (fr) 2008-01-08 2009-07-16 Array Biopharma Inc. Pyrrolopyridines en tant qu'inhibiteurs de kinase
CA2711741A1 (fr) * 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrrolopyridines en tant qu'inhibiteurs de kinase
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2010033941A1 (fr) 2008-09-22 2010-03-25 Array Biopharma Inc. Composés imidazo[1,2b]pyridazine substitués comme inhibiteurs de kinases trk
MY169791A (en) * 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
EP2348860B1 (fr) * 2008-10-31 2015-05-27 Genentech, Inc. Composés inhibiteurs de jak à la pyrazolopyrimidine et procédés
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2473041B1 (fr) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulateurs de points de contrôle du cycle cellulaire et leur utilisation en combinaison avec des inhibiteurs de kinase de point de contrôle
SG179083A1 (en) * 2009-09-11 2012-04-27 Cylene Pharmaceuticals Inc Pharmaceutically useful heterocycle-substituted lactams
NZ601324A (en) * 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
AU2011204407B2 (en) 2010-01-05 2015-05-07 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma GBM
EP2525659B1 (fr) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. COMPOSÉS PYRAZOLO[1,5-a]PYRIMIDINES EN TANT QU'INHIBITEURS DE mTOR
ME03376B (fr) 2010-05-20 2020-01-20 Array Biopharma Inc Composés macrocycliques comme inhibiteurs de la kinase trk
EP2937349B1 (fr) 2011-03-23 2016-12-28 Amgen Inc. Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et flt3
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013039854A1 (fr) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions et méthodes de traitement du cancer
CA2889919C (fr) 2012-11-16 2021-08-17 University Health Network Composes de pyrazolopyrimidine
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
WO2014143240A1 (fr) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
WO2015097121A1 (fr) 2013-12-23 2015-07-02 Norgine B.V. Composés utiles en tant que modulateurs du ccr9
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX373102B (es) 2014-06-05 2020-04-17 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
GB201517263D0 (en) * 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3368039A1 (fr) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (fr) 2016-05-18 2020-11-25 Loxo Oncology Inc. Préparation de (s)-n-(5-((r)-2-(2,5-difluorophényl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
AR110252A1 (es) * 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
SI3658557T1 (sl) * 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
EP3461480A1 (fr) 2017-09-27 2019-04-03 Onxeo Combinaison d'inhibiteurs de point de contrôle du cycle cellulaire de réponse à un dommage à l'adn et de belinostat pour traiter le cancer
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
US11155560B2 (en) 2018-10-30 2021-10-26 Kronos Bio, Inc. Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
AU2019394520A1 (en) * 2018-12-07 2021-07-01 Betta Pharmaceuticals Co., Ltd Tyrosine kinase inhibitors, compositions and methods there of
CA3134814A1 (fr) 2019-03-26 2020-10-01 Ventyx Biosciences, Inc. Ligands de pseudokinase tyk2
JP7635228B2 (ja) 2019-11-08 2025-02-25 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
CN114728167B (zh) 2019-11-25 2024-03-19 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
EP4717312A1 (fr) * 2024-09-27 2026-04-01 Perha Pharmaceuticals Derives de pyrazolo[1,5-a!pyrimidine utiles comme medicament

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0438730Y2 (fr) * 1986-03-26 1992-09-10
JP3039751U (ja) * 1996-12-09 1997-07-31 尚子 小園 鞄類用補助具
JP2002295682A (ja) * 2001-03-28 2002-10-09 Yazaki Corp 防水構造およびこの防水構造に用いられる座金部材
AU2003240488A1 (en) * 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
US7196092B2 (en) * 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002571A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
ES2285164T3 (es) * 2002-09-04 2007-11-16 Schering Corporation Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina.
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7557110B2 (en) * 2003-02-28 2009-07-07 Teijin Pharma Limited Pyrazolo[1,5-A] pyrimidine derivatives
US20070179161A1 (en) * 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP3940700B2 (ja) * 2003-05-22 2007-07-04 茂 相馬 楽器用ケース
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
JP3104094U (ja) * 2004-03-18 2004-09-02 チャン ホアン−リン 両用スーツケース
CN101321759A (zh) * 2005-10-06 2008-12-10 先灵公司 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
JP5052518B2 (ja) * 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
JP3174645U (ja) * 2012-01-19 2012-03-29 株式会社セイバン ランドセル

Also Published As

Publication number Publication date
US8211854B2 (en) 2012-07-03
CA2627623C (fr) 2014-04-22
NO20082093L (no) 2008-07-03
CN101360499B (zh) 2015-10-07
BRPI0616985A2 (pt) 2009-08-04
WO2007044441A3 (fr) 2007-07-26
NZ567151A (en) 2012-03-30
TWI421078B (zh) 2014-01-01
BRPI0616985B1 (pt) 2021-10-26
EP1942900B1 (fr) 2015-06-03
CN101360499A (zh) 2009-02-04
EP1942900A2 (fr) 2008-07-16
JP2012082234A (ja) 2012-04-26
WO2007044441A2 (fr) 2007-04-19
US20100125068A1 (en) 2010-05-20
AU2006302435A1 (en) 2007-04-19
JP5152922B2 (ja) 2013-02-27
JP2014062129A (ja) 2014-04-10
CA2627623A1 (fr) 2007-04-19
US20070082900A1 (en) 2007-04-12
JP5520325B2 (ja) 2014-06-11
JP2009511486A (ja) 2009-03-19
TW200800218A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
HUS2400038I1 (hu) Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok
IL195238A0 (en) Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
IL188248A0 (en) Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1796467A4 (fr) Inhibiteurs imidazo{4,5-b}pyrazinone de proteines kinases
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
LT3184526T (lt) Pirol[2,3-d]pirimidino dariniai kaip janus kinazės inhibitoriai
IL206084A0 (en) Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
WO2008058126A3 (fr) Dérivés d'imidazo[1,2-b]pyridazine et de pyrazolo[1,5-a]pyrimidine et utilisation de ceux-ci comme inhibiteurs de protéines kinases
EP1945222A4 (fr) Derives pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives
IL247884B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
ZA201004603B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and p13 kinase inhibitors, and their synthesis
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
EP1599482A4 (fr) Derives de pyrazolo 1,5-a pyrimidine
EP1670466A4 (fr) Preparation d'azabenzimidazoles trisubstitues en position 1,6,7 servant d'inhibiteurs des kinases
ZA200803173B (en) Pyrazolo [4,3-d] Pyrimidin-5-yl) Derivative used as PDE5 Inhibitors
ZA200809016B (en) 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
HK1112850A (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
HK1133653A (en) Imidazo [1,2-b] pyridazine and pyrazolo [1,5-a] pyrimidine derivatives and their use as protein kinase inhibitors
HK1112231A (en) Pyrazolo [1,5-a] pyrimidines as protein kinase inhibitors
HK1122301A (en) Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
HK1097743A (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
HK1090649A (en) Imidazo[1,5-a]pyrazine tyrosine kinase inhibitors